| Cranial Technologies, Inc. | |
| 10750 Columbia Pike, Ste 100, Silver Spring, Maryland 20901 | |
| (301) 681-3549 |
| Name | Cranial Technologies, Inc. |
|---|---|
| Organization Name | Cranial Technologies, Inc. |
| Location | 10750 Columbia Pike, Ste 100, Silver Spring, Maryland 20901 |
| Type | Prosthetic/Orthotic Supplier |
| Phone | (301) 681-3549 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
The Associated Press-NORC Center for Public Affairs Research has released the results of a major new survey that reveals the American people's list of issues they believe should be the focus of government attention in 2014. The same survey also explores the complex blend of personal, political, and ideological factors that lie behind such a list.
Patients suffering from chronic obstructive pulmonary disease (COPD) typically suffer from depression more frequently than those without COPD, resulting in higher levels of disability and illness and increasing the overall healthcare burden for the COPD population.
Roche today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy. The CHMP positive opinion clears the way for European Union approval and means that this group of patients may soon be able to benefit from earlier treatment with Tarceva.
According to psychologists, in addition to our physiological immune system, we also have a behavioral one: an unconscious code of conduct that helps us stay disease-free, including fear and avoidance of unfamiliar - and so possibly infected - people.
› Verified 7 days ago
| NPI Number | 1205338860 |
| Organization Name | CRANIAL TECHNOLOGIES INC |
| Type | Prosthetic/Orthotic Supplier |
| Address | 10750 Columbia Pike Ste 100, Silver Spring, MD 20901 |
| Phone Number | 844-447-5894 |
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
The Associated Press-NORC Center for Public Affairs Research has released the results of a major new survey that reveals the American people's list of issues they believe should be the focus of government attention in 2014. The same survey also explores the complex blend of personal, political, and ideological factors that lie behind such a list.
Patients suffering from chronic obstructive pulmonary disease (COPD) typically suffer from depression more frequently than those without COPD, resulting in higher levels of disability and illness and increasing the overall healthcare burden for the COPD population.
Roche today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy. The CHMP positive opinion clears the way for European Union approval and means that this group of patients may soon be able to benefit from earlier treatment with Tarceva.
According to psychologists, in addition to our physiological immune system, we also have a behavioral one: an unconscious code of conduct that helps us stay disease-free, including fear and avoidance of unfamiliar - and so possibly infected - people.
› Verified 7 days ago
News Archive
Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis' lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.
The Associated Press-NORC Center for Public Affairs Research has released the results of a major new survey that reveals the American people's list of issues they believe should be the focus of government attention in 2014. The same survey also explores the complex blend of personal, political, and ideological factors that lie behind such a list.
Patients suffering from chronic obstructive pulmonary disease (COPD) typically suffer from depression more frequently than those without COPD, resulting in higher levels of disability and illness and increasing the overall healthcare burden for the COPD population.
Roche today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for use of Tarceva(R) (erlotinib) as a maintenance therapy for people with advanced non-small cell lung cancer (NSCLC) and stable disease (cancer remains largely unchanged) after initial chemotherapy. The CHMP positive opinion clears the way for European Union approval and means that this group of patients may soon be able to benefit from earlier treatment with Tarceva.
According to psychologists, in addition to our physiological immune system, we also have a behavioral one: an unconscious code of conduct that helps us stay disease-free, including fear and avoidance of unfamiliar - and so possibly infected - people.
› Verified 7 days ago
Iglasses@fourcorners Type: Medicare Supplier Location: 10101 Colesville Rd, Silver Spring, Maryland 20901 Phone: (301) 754-0101 | |
Bosons Pharmaceutical Corp Type: Pharmacy Location: 12838 New Hampshire Ave, Silver Spring, Maryland 20904 Phone: (301) 622-0744 | |
Cranial Technologies, Inc. Type: Prosthetic/Orthotic Supplier Location: 10750 Columbia Pike, Silver Spring, Maryland 20901 Phone: (301) 681-3549 | |
Giant Pharmacy #135 Type: Pharmacy Location: 3860 International Dr, Silver Spring, Maryland 20906 Phone: (301) 598-3208 | |
Giant Pharmacy #301 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 13781 Connwcticut Ave, Silver Spring, Maryland 20906 Phone: (301) 603-7501 |